long intergenic non-protein coding RNA 2773Genealiases: []
Q-omics provides the consensus-scored LINC02773 profile across patient tissues and cancer cell-line models. LINC02773 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC02773 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC02773 RNA expression shows 12,920 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where LINC02773 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02773 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02773 survival associations across molecular data types. LINC02773 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02773 RNA expression–survival associations across cancer types. High LINC02773 expression shows unfavorable associations in KIRP, UVM, LGG and THYM, but favorable associations in SKCM and SARC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC02773 RNA expression.
This table summarizes LINC02773 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02773. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02773 shows lower tumor expression in KICH, LUSC, LUAD and BRCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher LINC02773 RNA expression in tumor versus normal tissue (log2 FC = +0.616, t-test p < 0.001).
This table shows molecular features associated with LINC02773 in patient tissues and cancer cell lines. In patient samples, LINC02773 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
